29.35
Viking Therapeutics Inc stock is traded at $29.35, with a volume of 2.01M.
It is down -1.97% in the last 24 hours and down -25.29% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$29.96
Open:
$29.45
24h Volume:
2.01M
Relative Volume:
0.51
Market Cap:
$3.30B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-31.56
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-12.33%
1M Performance:
-25.29%
6M Performance:
-49.70%
1Y Performance:
-7.42%
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VKTX
Viking Therapeutics Inc
|
29.35 | 3.30B | 0 | -99.15M | -74.25M | -0.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
451.43 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
663.70 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
648.80 | 39.35B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
265.42 | 34.31B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
112.33 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-07-25 | Initiated | Citigroup | Neutral |
Dec-02-24 | Initiated | Piper Sandler | Overweight |
Nov-22-24 | Initiated | B. Riley Securities | Buy |
Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
Sep-11-24 | Initiated | JP Morgan | Overweight |
Jun-27-24 | Initiated | Morgan Stanley | Overweight |
May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Mar-26-24 | Reiterated | Oppenheimer | Outperform |
Mar-07-24 | Initiated | Jefferies | Buy |
Feb-28-24 | Reiterated | Oppenheimer | Outperform |
May-31-23 | Resumed | ROTH MKM | Buy |
Mar-28-23 | Reiterated | Maxim Group | Buy |
Mar-17-23 | Initiated | Stifel | Buy |
Jul-29-21 | Resumed | BTIG Research | Buy |
May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
May-05-20 | Initiated | Chardan Capital Markets | Buy |
May-01-20 | Initiated | BTIG Research | Buy |
Jul-16-19 | Initiated | Oppenheimer | Outperform |
Jun-25-19 | Initiated | Stifel | Buy |
Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-14-19 | Reiterated | Maxim Group | Buy |
Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
Dec-12-18 | Initiated | B. Riley FBR | Buy |
Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
Sep-18-18 | Reiterated | Maxim Group | Buy |
Sep-18-18 | Reiterated | Raymond James | Outperform |
Jul-20-18 | Initiated | SunTrust | Buy |
Jun-28-18 | Initiated | Raymond James | Outperform |
Jun-01-18 | Reiterated | Laidlaw | Buy |
May-31-18 | Reiterated | Maxim Group | Buy |
Mar-26-18 | Resumed | H.C. Wainwright | Buy |
Nov-28-17 | Reiterated | Maxim Group | Buy |
Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 1.2%Should You Sell? - MarketBeat
Why Viking Therapeutics Inc. (VKTX) Went Down on Monday - MSN
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today - Benzinga
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today - The Motley Fool
2 Stocks to Buy With Less Than $40 - Yahoo Finance
Viking Therapeutics Stock Price Forecast for 2025 - Markets.com
Viking Therapeutics started at neutral by Citi - MSN
How to Take Advantage of moves in (VKTX) - Stock Traders Daily
Raymond James Boosts Viking Therapeutics (NASDAQ:VKTX) Price Target to $125.00 - MarketBeat
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip? - sharewise
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10% - MSN
Viking Therapeutics price target lowered to $96 from $109 at B. Riley - Yahoo Finance
2 Stocks That Could Soar Again in 2025 - Yahoo Finance
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year - MSN
B. Riley Adjusts Price Target on Viking Therapeutics to $96 From $109, Keeps Buy Rating - Marketscreener.com
Citigroup Initiates Viking Therapeutics at Neutral With $38 Price Target -February 07, 2025 at 08:52 am EST - Marketscreener.com
Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating - Marketscreener.com
Citigroup initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Viking Therapeutics Reports Strong Trials and Financial Health - TipRanks
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why. - Yahoo
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
Has the Bubble Burst for Viking Therapeutics Stock? - MSN
Viking Therapeutics price target raised to $125 from $122 at Raymond James - TipRanks
Viking Therapeutics Inc (VKTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Viking Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress - TipRanks
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. - Yahoo! Voices
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress - MSN
Viking Therapeutics : February 2025 Corporate Presentation - Marketscreener.com
VIKING THERAPEUTICS Earnings Results: $VKTX Reports Quarterly Earnings - Nasdaq
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates - Benzinga
Viking stock slides 8% following Q4 report, pipeline update - Seeking Alpha
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Fin - GuruFocus.com
Viking Therapeutics, Inc. (VKTX): One of January’s Biggest Losers - Insider Monkey
Viking Therapeutics reports Q4 EPS (32c), consensus (27c) - TipRanks
Viking's Obesity Drug Achieves 14.7% Weight Loss, Phase 3 Launch Set for Q2 - StockTitan
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - Yahoo Finance
BlackRock, Inc. Expands Stake in Viking Therapeutics Inc - GuruFocus.com
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - MSN
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
Why Does Jim Cramer Prefer Eli Lilly (LLY) Over Viking Therapeutics? - MSN
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha
Can Viking Touch The $100 Mark? - RTTNews
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Janney Montgomery Scott LLC - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by U.S. Capital Wealth Advisors LLC - MarketBeat
Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $106.75 - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Institute for Wealth Management LLC. - MarketBeat
Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday - MarketBeat
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? - MSN
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):